Pharmaceutical Companies Increase Prices of Medicines for Treatment of Oncological Diseases Upon Introduction of Reference Prices
Further unscrupulous actions from the side of some pharmaceutical companies are recorded upon introduction of reference prices.
At this point, it concerns expensive medicines for treatment of oncological diseases funded within State Universal Healthcare Program, for which reference prices are not set.
Namely, some of the companies artificially significantly increased prices of these medicines. It should be noted that according to the data of National Health Agency, companies selling expensive medicines for treatment of oncological diseases set identic prices for the medicines of the same title. According to preliminary assessment, dishonest agreement and improper use of dominancy may have place, which significantly harms citizens and the State financing treatment of oncological patients.
National Competition Agency is involved in the process of study of dishonest actions from the part of pharmaceutical companies.
It is publicly known, that within State Universal Healthcare Program, 25,000 GEL is allocated annually per one beneficiary for chemoradiation hormone therapy. Artificially increased prices limit accessibility of oncological patients to medicines.
It’s regretful, that artificial price increase continues from the side of certain pharmaceutical companies.
The Ministry of Health repeatedly declared that artificial increase of medicines prices is unacceptable and the Ministry will strictly respond to each irregularity.